Natco Pharma Q4 net down 22.5% at ₹93 cr

Our Bureau Hyderabad | Updated on June 17, 2020

Natco Pharma Ltd’s consolidated net profit declined 22.5 per cent to ₹93 crore in the fourth quarter ended March 31, against ₹120 crore profit recorded in the corresponding quarter last year.

The total revenue of the Hyderabad-based company was marginally down at ₹477 crore (₹487 crore).

For the full year ended March 31, the drug maker posted 9 per cent decline in revenue at ₹2,022 crore against ₹2,225 crore in previous fiscal. The net profit for the period declined 29 per cent to ₹458 crore (₹642 crore).

“The overall decline in revenue and profits, from the prior year, was primarily due to continued decline in Hepatitis C product portfolio and to an extent in oncology segment due to pricing pressures,’’ the company said in a release.

The company also faced slowdown in business operations during the fourth quarter due to supply chain issues amidst Covid-19 concerns, which were subsequently resolved, it added.

The board of directors recommended a fourth interim dividend of ₹1.00 per equity share of ₹2 each, resulting in a total dividend payout of ₹6.75 per equity share for the year.

Published on June 17, 2020

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like